Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CAT-152: Phase I/IIa data; Phase II

In a 24-patient Phase I/IIa trial, 11 of 16 CAT-152 patients did not

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE